Qibeian (iparomlimab/tuvonralimab) / Sound Biologics, Qilu Pharma - LARVOL DELTA

A Phase 2 Trial of QLC5508 (MHB088C) Plus QL1706 or QL2107 as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (IASLC-WCLC 2026) - "This study aimed to evaluate the efficacy and safety of QLC5508 in combination with QL1706 (iparomlimab and tuvonralimab, a bifunctional antibody targeting PD-1 and CTLA-4) or QL2107 (a pembrolizumab biosimilar) as first-line treatment in patients with ES-SCLC. Conclusions : QLC5508 in combination with QL1706 or QL2107 as first-line treatment showed promising anti-tumor activity and a manageable safety profile in patients with ES-SCLC. The combined regimen of B7H3 ADC plus PD-1 or PD-1/CTLA-4 antibody is a potential therapy for ES-SCLC and worthy of further exploration."

Clinical • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • CD276

Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus (clinicaltrials.gov) - P2 | N=35 | Recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor • Thrombosis

Neoadjuvant Iparomlimab and Tuvonralimab(PD-1/CTLA-4 bispecific antibody) combined with lenvatinib for high-risk localized and locally advanced renal cell carcinoma (ESMO 2026) - No abstract available

Bispecific • Clinical • Metastases • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CTLA4 • PD-1

Case Report: Iparomlimab and Tuvonralimab-based therapy for epithelioid malignant peritoneal mesothelioma: a three-case series. (PubMed, Front Oncol) - "QL1706 plus bevacizumab subsequently produced stable disease with symptomatic improvement for approximately 7 months...QL1706 plus dose-reduced lenvatinib achieved a partial response that remained ongoing for more than 10 months...QL1706-based therapy achieved disease control in all three patients with EMPM who had limited conventional treatment options, including a durable response in an elderly patient with PD-L1-negative disease and rapid tumor regression with QL1706 monotherapy. The contrasting clinical courses suggest that overall benefit depends not only on tumor sensitivity but also on the accompanying treatment strategy and baseline organ function."

Journal • Glomerulonephritis • Mesothelioma • Nephrology • Oncology • Peritoneal Mesothelioma • Renal Disease • Solid Tumor • PD-L1

CASTLE-ZS-04: Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer. (clinicaltrials.gov) - P2 | N=180 | Not yet recruiting | Sponsor: Fudan University

New P2 trial • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

Neoadjuvant QL1706 (Iparomlimab-Tuvonralimab) Plus Lenvatinib for Potentially Resectable Hepatocellular Carcinoma: Preliminary Results from an Exploratory Phase II Study (ESMO 2026) - No abstract available

Clinical • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Iparomlimab and Tuvonralimab (QL1706) Combined with Lenvatinib and GEMOX as First-line Treatment for Advanced Biliary Tract Cancer (SPRING): A Multi-Center, Single-arm, Phase 2 Study (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Iparomlimab and tuvonralimab (QL1706) plus lenvatinib and hepatic arterial infusion chemotherapy (HAIC) as first-line treatment for unresectable intrahepatic cholangiocarcinoma: a single-arm, phase II study (ESMO 2026) - No abstract available

Clinical • P2 data • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Iparomlimab and Tuvonralimab(PD-1/CTLA-4 bifunctional antibody) plus lenvatinib as second line and beyond treatment for advanced renal cell carcinoma (ESMO 2026) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CTLA4 • PD-1

A Prospective, Single‑Arm, Multicenter Clinical Study of Epalolitoworelimab (a PD‑1/CTLA‑4 Combination Antibody) Combined with Lenvatinib in the Perioperative Treatment of High‑Risk Localized and Locally Advanced Renal Clear Cell Carcinoma (ChiCTR) - P4 | N=54 | Not yet recruiting | Sponsor: Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School; Nanjing Drum Tower Hospital The Affiliated Hospital of Nanji

New P4 trial • Clear Cell Carcinoma • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

ZSPAC-22: Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC (clinicaltrials.gov) - P2 | N=56 | Not yet recruiting | Sponsor: Shanghai Zhongshan Hospital

New P2 trial • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Prostate Cancer • Solid Tumor

Iparomlimab and Tuvonralimab (QL1706) Combined with Apatinib and Capecitabine for the Treatment of Advanced Esophageal Squamous Cell Carcinoma (ESCC): A Single-Arm, Open-Label, Phase II Clinical Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase 3 trial (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Cervical Cancer • Oncology • Solid Tumor

QL1706 Plus Pm-Pac and Platinum in the Treatment of Stage III Unresectable NSCLC: Preliminary Results From Dynamic-Duo Study (IASLC-WCLC 2026) - P2 | "Participants received induction therapy with three cycles (administered every 3 weeks) of QL1706 (5 mg/kg) plus pm-Pac (230 mg/m2, followed by a dose escalation to 300 mg/m2 from the second cycle if no predefined toxicities were observed) and a platinum agent (cisplatin 70 mg/m2 or carboplatin AUC 5 mg/mL/min). The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate (DCR), surgical conversion rate (SCR), pathological complete response (pCR), major pathological response (MPR), R0 resection rate, 18-month event free survival rate (EFS), overall survival (OS), and safety."

Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR • ROS1

Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and definitive radiotherapy as first-line treatment for oligometastatic cervical cancer: a single-arm, phase II study (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Cervical Cancer • Oncology • Solid Tumor

Iparolimab and Tuvonralimab (QL1706) Plus Hepatic Arterial Infusion Chemotherapy (HAIC) in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma (ESMO 2026) - No abstract available

Metastases • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

Iparomlimab and Tuvonralimab in Combination with Trastuzumab Rezetecan for the Treatment of HER2-low Advanced Breast Cancer: A Single-arm, Multicenter, Phase II Clinical Study (ChiCTR) - P2 | N=42 | Not yet recruiting | Sponsor: Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute); Shandong First Medical University an

New P2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • HER-2

CCGLC-017: Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence (clinicaltrials.gov) - P2 | N=26 | Recruiting | Sponsor: Tongji Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor • PD-L1

QL1706 plus disitamab vedotin in platinum-refractory or platinum-intolerant unresectable locally advanced or metastatic penile squamous cell carcinoma: BRIGHT-01, a prospective phase II study (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Penile Cancer • Squamous Cell Carcinoma

Neoadjuvant Iparomlimab and Tuvonralimab (PD-1/CTLA-4 Bifunctional Antibody) Plus Chemotherapy Enables Radical Surgery in Locally Advanced Cervical Cancer (ESMO 2026) - No abstract available

Clinical • Metastases • Surgery • Cervical Cancer • Oncology • Solid Tumor • CTLA4

Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC (clinicaltrials.gov) - P2 | N=108 | Recruiting | Sponsor: Zhongnan Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Rectal Cancer • Solid Tumor

QL1706 (PD-1/CTLA-4 bispecific antibody) plus bevacizumab specific for patients with hepatocellular carcinoma combined with lung metastasis: A secondary analysis of a prospective, single-arm, phase Ib/II study. (ASCO 2026) - P1/2 | "QL1706 plus bevacizumab demonstrated promising antitumor activity and a manageable safety profile in patients with HCC and lung metastases. The high response rate observed in lung lesions highlights the potential of intensified immunotherapy combined with anti-VEGF therapy for this subgroup, warranting further validation in phase III trials. Treatment-emergent adverse events of QL1706 / QL1604 and bevacizumab."

Bispecific • Clinical • P1/2 data • Hepatocellular Cancer • Oncology • Solid Tumor • CTLA4 • PD-1

A prospective, single-arm, multicenter, phase II study of QL1706 plus TFOX as first-line therapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Gastric Adenocarcinoma • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

Neoadjuvant Iparomlimab and Tuvonralimab (PD-1/CTLA-4 bifunctional antibody) Combined With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (ESMO 2026) - No abstract available

Clinical • Metastases • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CTLA4